Riskpilot← Back to searchSign inGet full accessDanuta's Dermo Medika AB
ABActiveOrg 5567934962Bågfilsgatan 23Medical specialists activities · NACE 8622Est. 20091 employees
Revenue 2025
SEK 4,8M
+5% vs 2024
EBITDA margin
35.4%
+31% vs 2024
Equity ratio
49.5%
Financial strength
Net profit 2025
SEK 1M
-6% vs 2024
| Revenue | SEK 4,8M | +5% |
| EBITDA | SEK 1,7M | +31% |
| Net profit | SEK 1M | -6% |
| Total assets | SEK 3,8M | +14% |
| Equity | SEK 1,9M | +14% |
| Employees | 1 | — |
Legal name
Danuta's Dermo Medika AB
Org number
5567934962
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
13 november 2009
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolagts verksamhet skall bestå i läkarverksamhet med inriktning på hudsjukdomar samt övriga medicinska konsultationer och därmed förenlig verksamhet.
Address
Bågfilsgatan 23
Phone
+4640499795
Email
zwolinski.danuta@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 292 | 4 362 | 4 398 | 4 608 | 4 845 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 273 | 1 173 | −156 | 1 307 | 1 716 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 273 | 1 173 | −156 | 1 307 | 1 716 |
| Net financials | — | — | 19 | 37 | 18 |
| Profit before tax | 400 | 1 137 | 517 | 1 385 | 1 295 |
| Tax | −88 | −241 | −122 | −296 | −272 |
| Net profit | 312 | 896 | 395 | 1 089 | 1 023 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 615 | 4 533 | 3 534 | 3 357 | 3 815 |
| Equity | 2 450 | 2 370 | 1 968 | 1 657 | 1 889 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 206 | 166 | 223 | 398 | 183 |
| Total debt | 206 | 166 | 223 | 398 | 183 |
EBITDA margin
35.4%
This company
15.8%
Market median
+124% vs market
20212025
Equity ratio
49.5%
This company
38.2%
Market median
+30% vs market
20212025
Return on equity
54.2%
This company
18.4%
Market median
+195% vs market
20212025
Net profit margin
21.1%
This company
8.1%
Market median
+160% vs market
20212025
Asset turnover
1.27×
This company
1.12×
Market median
+13% vs market
20212025
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Audit | 2026 | |
| Former (1) | ||
PO | Audit | 2022 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Danuta's Dermo Medika AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Paul Olof Jakob Ekman | Audit | 0 companies |
| Ann-Christine Lill Inger Lindvall | Audit | 0 companies |
| Daniel Rickard Kaj Zwolinski | Deputy Board Member | 0 companies |
| Danuta Zwolinski | Board of Directors | 0 companies |
| Daniel Rickard Kaj Zwolinski | Deputy Board Member | 0 companies |